Lineage Cell Therapeutics (LCTX) Projected to Post Quarterly Earnings on Tuesday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is projected to announce its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $4.8010 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.07. The business had revenue of $6.61 million for the quarter, compared to analysts’ expectations of $1.96 million. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. On average, analysts expect Lineage Cell Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lineage Cell Therapeutics Stock Up 4.6%

LCTX stock traded up $0.07 during mid-day trading on Tuesday, hitting $1.49. The company had a trading volume of 568,296 shares, compared to its average volume of 1,161,428. The company has a market capitalization of $370.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.60. Lineage Cell Therapeutics has a 12-month low of $0.43 and a 12-month high of $2.09. The company has a 50-day moving average price of $1.64 and a 200 day moving average price of $1.69.

Institutional Trading of Lineage Cell Therapeutics

A number of large investors have recently made changes to their positions in the business. Kestra Advisory Services LLC increased its holdings in shares of Lineage Cell Therapeutics by 174.7% in the 4th quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock worth $46,000 after buying an additional 17,647 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock worth $91,000 after buying an additional 18,092 shares during the last quarter. DLD Asset Management LP bought a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth about $33,000. Raymond James Financial Inc. increased its holdings in shares of Lineage Cell Therapeutics by 30.3% in the 3rd quarter. Raymond James Financial Inc. now owns 90,381 shares of the company’s stock worth $153,000 after buying an additional 21,001 shares during the last quarter. Finally, Jain Global LLC increased its holdings in shares of Lineage Cell Therapeutics by 202.3% in the 4th quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after buying an additional 26,000 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on LCTX shares. D. Boral Capital reiterated a “buy” rating and issued a $3.00 price target on shares of Lineage Cell Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 24th. Canaccord Genuity Group started coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, B. Riley Financial boosted their price target on shares of Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $6.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.